Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study

Carter M. Owen, Lubna Pal, Sunni L. Mumford, Ruth Freeman, Barbara Isaac, Linda McDonald, Nanette Santoro, Hugh S. Taylor, Erin F. Wolff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To measure skin wrinkles and rigidity in menopausal women of varying race/ethnicity with or without hormone therapy (HT) for up to four years. Design Randomized, double-blind, placebo-controlled trial. Setting Academic medical centers. Patient(s) Women (42–58 years of age) within 36 months of last menstrual period and enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Intervention(s) Treatment with 0.45 mg oral conjugated equine estrogens (CEE), transdermal E2 (50 μg/d) with micronized P (200 mg daily), or placebo for 4 years. Main Outcome Measure(s) Skin wrinkles were assessed at 11 locations on the face and neck, and skin rigidity was assessed at the forehead and cheek at baseline and yearly for 4 years. Result(s) Neither total wrinkle score nor total rigidity score was significantly different at baseline or over the 4-year follow-up among patients randomized to CEE, E2, or placebo. Skin wrinkle and rigidity scores were primarily affected by race/ethnicity, with scores being significantly different between races for almost all of the wrinkle parameters and for all of the rigidity measures. There was no association between race and response to HT for total wrinkle or rigidity scores. Black women had the lowest wrinkle scores compared with white women across all 4 years. In general, skin rigidity decreased in all groups over time, but black women had significantly reduced total facial rigidity compared with white women after 4 years. Conclusion(s) Race is the strongest predictor of the advancement of skin aging in the 4 years following menopause. HT does not appear to affect skin wrinkles or rigidity at most facial locations. Clinical Trial Registration Number NCT00154180.

Original languageEnglish (US)
Pages (from-to)1170-1175.e3
JournalFertility and Sterility
Volume106
Issue number5
DOIs
StatePublished - Oct 1 2016

Fingerprint

Estrogens
Hormones
Skin
Conjugated (USP) Estrogens
Placebos
Skin Aging
Forehead
Cheek
Therapeutics
Menopause
Neck
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • hormone therapy
  • Menopause
  • race
  • skin rigidity
  • skin wrinkles

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity : four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. / Owen, Carter M.; Pal, Lubna; Mumford, Sunni L.; Freeman, Ruth; Isaac, Barbara; McDonald, Linda; Santoro, Nanette; Taylor, Hugh S.; Wolff, Erin F.

In: Fertility and Sterility, Vol. 106, No. 5, 01.10.2016, p. 1170-1175.e3.

Research output: Contribution to journalArticle

Owen, Carter M. ; Pal, Lubna ; Mumford, Sunni L. ; Freeman, Ruth ; Isaac, Barbara ; McDonald, Linda ; Santoro, Nanette ; Taylor, Hugh S. ; Wolff, Erin F. / Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity : four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. In: Fertility and Sterility. 2016 ; Vol. 106, No. 5. pp. 1170-1175.e3.
@article{33193f8728344babb71120a73769ce33,
title = "Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study",
abstract = "Objective To measure skin wrinkles and rigidity in menopausal women of varying race/ethnicity with or without hormone therapy (HT) for up to four years. Design Randomized, double-blind, placebo-controlled trial. Setting Academic medical centers. Patient(s) Women (42–58 years of age) within 36 months of last menstrual period and enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Intervention(s) Treatment with 0.45 mg oral conjugated equine estrogens (CEE), transdermal E2 (50 μg/d) with micronized P (200 mg daily), or placebo for 4 years. Main Outcome Measure(s) Skin wrinkles were assessed at 11 locations on the face and neck, and skin rigidity was assessed at the forehead and cheek at baseline and yearly for 4 years. Result(s) Neither total wrinkle score nor total rigidity score was significantly different at baseline or over the 4-year follow-up among patients randomized to CEE, E2, or placebo. Skin wrinkle and rigidity scores were primarily affected by race/ethnicity, with scores being significantly different between races for almost all of the wrinkle parameters and for all of the rigidity measures. There was no association between race and response to HT for total wrinkle or rigidity scores. Black women had the lowest wrinkle scores compared with white women across all 4 years. In general, skin rigidity decreased in all groups over time, but black women had significantly reduced total facial rigidity compared with white women after 4 years. Conclusion(s) Race is the strongest predictor of the advancement of skin aging in the 4 years following menopause. HT does not appear to affect skin wrinkles or rigidity at most facial locations. Clinical Trial Registration Number NCT00154180.",
keywords = "hormone therapy, Menopause, race, skin rigidity, skin wrinkles",
author = "Owen, {Carter M.} and Lubna Pal and Mumford, {Sunni L.} and Ruth Freeman and Barbara Isaac and Linda McDonald and Nanette Santoro and Taylor, {Hugh S.} and Wolff, {Erin F.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.fertnstert.2016.06.023",
language = "English (US)",
volume = "106",
pages = "1170--1175.e3",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity

T2 - four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study

AU - Owen, Carter M.

AU - Pal, Lubna

AU - Mumford, Sunni L.

AU - Freeman, Ruth

AU - Isaac, Barbara

AU - McDonald, Linda

AU - Santoro, Nanette

AU - Taylor, Hugh S.

AU - Wolff, Erin F.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective To measure skin wrinkles and rigidity in menopausal women of varying race/ethnicity with or without hormone therapy (HT) for up to four years. Design Randomized, double-blind, placebo-controlled trial. Setting Academic medical centers. Patient(s) Women (42–58 years of age) within 36 months of last menstrual period and enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Intervention(s) Treatment with 0.45 mg oral conjugated equine estrogens (CEE), transdermal E2 (50 μg/d) with micronized P (200 mg daily), or placebo for 4 years. Main Outcome Measure(s) Skin wrinkles were assessed at 11 locations on the face and neck, and skin rigidity was assessed at the forehead and cheek at baseline and yearly for 4 years. Result(s) Neither total wrinkle score nor total rigidity score was significantly different at baseline or over the 4-year follow-up among patients randomized to CEE, E2, or placebo. Skin wrinkle and rigidity scores were primarily affected by race/ethnicity, with scores being significantly different between races for almost all of the wrinkle parameters and for all of the rigidity measures. There was no association between race and response to HT for total wrinkle or rigidity scores. Black women had the lowest wrinkle scores compared with white women across all 4 years. In general, skin rigidity decreased in all groups over time, but black women had significantly reduced total facial rigidity compared with white women after 4 years. Conclusion(s) Race is the strongest predictor of the advancement of skin aging in the 4 years following menopause. HT does not appear to affect skin wrinkles or rigidity at most facial locations. Clinical Trial Registration Number NCT00154180.

AB - Objective To measure skin wrinkles and rigidity in menopausal women of varying race/ethnicity with or without hormone therapy (HT) for up to four years. Design Randomized, double-blind, placebo-controlled trial. Setting Academic medical centers. Patient(s) Women (42–58 years of age) within 36 months of last menstrual period and enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Intervention(s) Treatment with 0.45 mg oral conjugated equine estrogens (CEE), transdermal E2 (50 μg/d) with micronized P (200 mg daily), or placebo for 4 years. Main Outcome Measure(s) Skin wrinkles were assessed at 11 locations on the face and neck, and skin rigidity was assessed at the forehead and cheek at baseline and yearly for 4 years. Result(s) Neither total wrinkle score nor total rigidity score was significantly different at baseline or over the 4-year follow-up among patients randomized to CEE, E2, or placebo. Skin wrinkle and rigidity scores were primarily affected by race/ethnicity, with scores being significantly different between races for almost all of the wrinkle parameters and for all of the rigidity measures. There was no association between race and response to HT for total wrinkle or rigidity scores. Black women had the lowest wrinkle scores compared with white women across all 4 years. In general, skin rigidity decreased in all groups over time, but black women had significantly reduced total facial rigidity compared with white women after 4 years. Conclusion(s) Race is the strongest predictor of the advancement of skin aging in the 4 years following menopause. HT does not appear to affect skin wrinkles or rigidity at most facial locations. Clinical Trial Registration Number NCT00154180.

KW - hormone therapy

KW - Menopause

KW - race

KW - skin rigidity

KW - skin wrinkles

UR - http://www.scopus.com/inward/record.url?scp=84994875660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994875660&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2016.06.023

DO - 10.1016/j.fertnstert.2016.06.023

M3 - Article

AN - SCOPUS:84994875660

VL - 106

SP - 1170-1175.e3

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -